Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome.
Hyperandrogenism, a main clinical feature of polycystic ovary syndrome (PCOS), is thought to result from enhanced ovarian and adrenal androgen generation. To investigate the contribution of peripheral steroidogenesis, we used an oral challenge with dehydroepiandrosterone (DHEA) and analyzed its downstream conversion toward androgens in eight women with PCOS (age, 20-32 yr; body mass index, 20-41 kg/m(2)) and eight healthy women matched for age and body mass index. They underwent frequent serum sampling and urine collection for 8 h on three occasions: at baseline, and after 4 d of dexamethasone (Dex; 4 x 0.5 mg/d), followed by ingestion of 100 mg DHEA or placebo. Dex induced similar significant suppression of circulating steroids in both groups. The oral DHEA challenge led to similar significant increases in the area under the concentration-time curve (0-8 h after Dex) of serum DHEA, DHEA sulfate, androstenedione, and testosterone. However, after oral DHEA, PCOS women had significantly higher increases in serum 5 alpha-dihydrotestosterone (P < 0.01), its main metabolite androstanediol glucuronide (P < 0.05), and the 5 alpha-reduced urinary androgen metabolite androsterone (P < 0.05). PCOS women also had significantly higher baseline excretion of 5 alpha-reduced glucocorticoid (P < 0.01) and mineralocorticoid metabolites (P < 0.05). Taken together, these data indicate enhanced peripheral 5 alpha-reductase activity in PCOS. Thus, not only ovary and adrenal, but also liver and peripheral target tissues, significantly contribute to steroid alterations in PCOS.
Fassnacht
Martin
M
Department of Medicine, Endocrine and Diabetes Unit, University of Würzburg, 97080 Würzburg, Germany.
Schlenz
Nadine
N
Schneider
Susanne B
SB
Wudy
Stefan A
SA
Allolio
Bruno
B
Arlt
Wiebke
W
D000328:Adult; D000728:Androgens / Q000378:metabolism; D042944:Cholestenone 5 alpha-Reductase; D018592:Cross-Over Studies; D003687:Dehydroepiandrosterone / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D013196:Dihydrotestosterone / Q000097:blood; D005260:Female; D005938:Glucocorticoids / Q000494:pharmacology; D006728:Hormones / Q000097:blood; D006801:Humans; D010088:Oxidoreductases / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000201:enzymology* / Q000652:urine
D000728:Androgens; D005938:Glucocorticoids; D006728:Hormones; D013196:Dihydrotestosterone; D003687:Dehydroepiandrosterone; D003907:Dexamethasone; D010088:Oxidoreductases; D042944:Cholestenone 5 alpha-Reductase